FDA records linked by MedtechLedger show SmartWise Sweden AB as the applicant on K254051, an Extroducer Infusion Catheter System filing received 17 December 2025 and decided 11 September 2026 with decision code SESE, substantially equivalent. The same product name appears in an earlier FDA clearance letter, K213442/S001, dated 10 June 2022, addressed to SmartWise Sweden AB at Alfred Nobels allé 150, Tullinge, Sweden. That address is a filing address in FDA correspondence, not a verified headquarters. [1][2][3]
Documented FDA filings
The K254051 record lists the device as Extroducer Infusion Catheter System, regulation number 870.1210, device class 2, product code KRA, advisory committee Cardiovascular, clearance type Traditional, and third-party review flag No. The decision description reads Substantially Equivalent, and the record notes a summary is available. The FDA 510(k) database page for K254051 shows the same 09/11/2026 decision date and Cardiovascular review panel. [1][2]
The 2022 clearance letter covers K213442/S001 under the same trade name, regulation number and product code, with regulatory class II. Its device description states that the Extroducer Infusion Catheter System is a minimally invasive device for administering diagnostic or therapeutic solutions through the vascular wall directly to perivascular tissue of adult patients, penetrating the vascular wall at a selected site and then delivering the solution. The letter names the Bullfrog Micro-Infusion Device (K161402), manufactured by Mercator MedSystems, Inc., as predicate device. [3]
Applicant, brand and corporate context
SmartWise Sweden AB is the applicant identified in the FDA records. Published SmartCella material describes SmartCella as a biotech company founded in 2014 and built on research from Karolinska Institutet, operating in Targeted Delivery and Regenerative Medicines, with the Extroducer named among its delivery platforms. A SmartCella milestones page states that ProCella and SmartWise were founded in 2015 and that SmartCella Holding AB was formed in 2020. These pages present SmartWise within the SmartCella account; the FDA filings themselves name only SmartWise Sweden AB as applicant. [1][3][8][9]
Device description as published
SmartCella's website describes the Extroducer as a first-in-class endovascular delivery device designed to deliver advanced therapies directly into hard-to-reach areas of the body. It states that, in animal studies, multiple infusions could be performed in extravascular tissue after exit of the vascular system, and that the device can be integrated with most off-the-shelf microcatheters and navigated into the microvasculature. The page also references work in tissues such as heart, kidney, pancreas and liver. These are manufacturer statements, not FDA findings of safety or effectiveness. [4]
The 2022 FDA letter's device description is narrower in scope: administration of diagnostic or therapeutic solutions through the vascular wall to perivascular tissue in adult patients. The K254051 record identifies the device only by name, regulation, class and product code, without a published indication statement in the retrieved record. [1][3]
Related clinical research listing
A ClinicalTrials.gov record, NCT07575191, is titled for safety and performance of a novel infusion catheter system for peri/intratumoral gemcitabine delivery in patients with pancreatic cancer. The retrieved record shows first submission on 5 April 2026, first posting on 8 May 2026, and last update posted 12 June 2026, with last verification in June 2026. The retrieved text does not name the device sponsor or confirm that the studied catheter is the Extroducer, so the connection remains unverified. [7]

